NASDAQ:RVNC

Revance Therapeutics Stock Forecast, Price & News

$28.16
-0.01 (-0.04 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.92
Now: $28.16
$29.22
50-Day Range
$24.03
MA: $27.35
$29.30
52-Week Range
$14.50
Now: $28.16
$34.62
Volume304,610 shs
Average Volume441,927 shs
Market Capitalization$2.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
Revance Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400
Employees470
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$410,000.00
Book Value$5.00 per share

Profitability

Net Income$-159,430,000.00
Net Margins-5,818.87%

Miscellaneous

Market Cap$2.01 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Recap: Revance Therapeutics Q4 Earnings
February 22, 2021 |  finance.yahoo.com
Here's what Wall Street expects from Revance Therapeutics's earnings report
February 20, 2021 |  markets.businessinsider.com
Revance Therapeutics's Earnings Outlook
February 19, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

295th out of 2,021 stocks

Pharmaceutical Preparations Industry

130th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$28.16
-0.01 (-0.04 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

Is Revance Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Revance Therapeutics?

Wall Street analysts have given Revance Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Revance Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Revance Therapeutics
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Sunday, February, 21st. The biopharmaceutical company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.01. The biopharmaceutical company had revenue of $11.13 million for the quarter, compared to analyst estimates of $10.16 million. Revance Therapeutics had a negative net margin of 5,818.87% and a negative trailing twelve-month return on equity of 85.72%.
View Revance Therapeutics' earnings history
.

How has Revance Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RVNC stock has increased by 56.7% and is now trading at $28.16.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RVNC?

5 equities research analysts have issued 12-month target prices for Revance Therapeutics' stock. Their forecasts range from $31.00 to $45.00. On average, they anticipate Revance Therapeutics' share price to reach $36.40 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts' price targets for Revance Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mr. Mark J. Foley, Pres, CEO & Director (Age 56, Pay $866.13k)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 46, Pay $621.33k)
  • Dr. Abhay Joshi, COO, Pres of R&D and Product Operations (Age 58, Pay $699.21k)
  • Mr. Dustin S. Sjuts, Chief Commercial Officer of Aesthetics & Therapeutics (Age 41, Pay $658.02k)
  • Mr. Aubrey Rankin, Pres of Innovation & Technology and Director (Age 46)
  • Jessica Serra, Head of Investor Relations & ESG
  • Mr. Dwight Moxie, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway, VP of Marketing
  • Mr. Justin Ford, Sr. VP of HR & Head of People

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Carnegie Capital Asset Management LLC (0.02%).
View institutional ownership trends for Revance Therapeutics
.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC.
View insider buying and selling activity for Revance Therapeutics
or view top insider-selling stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $28.16.

How much money does Revance Therapeutics make?

Revance Therapeutics has a market capitalization of $2.01 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis.

How many employees does Revance Therapeutics have?

Revance Therapeutics employs 470 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

Where are Revance Therapeutics' headquarters?

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.